High RSF1 protein expression is an independent prognostic feature in prostate cancer

Authors

  • Doris Höflmayer Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Moslim Hamuda Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Cornelia Schroeder General, Visceral and Thoracic Surgery Department and Clinic, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Claudia Hube-Magg Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Ronald Simon Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Cosima Göbel Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Andrea Hinsch Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Sören Weidemann Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Katharina Möller Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Jacob R. Izbicki General, Visceral and Thoracic Surgery Department and Clinic, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Frank Jacobsen Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Tim Mandelkow Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Niclas C. Blessin Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Florian Lutz Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Florian Viehweger Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Guido Sauter Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Eike Burandt Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Patrick Lebok Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Maximilian Lennartz Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Christoph Fraune Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Sarah Minner Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Sarah Bonk General, Visceral and Thoracic Surgery Department and Clinic, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Hartwig Huland Martini-Clinic, Prostate Cancer Centre, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Markus Graefen Martini-Clinic, Prostate Cancer Centre, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  • Thorsten Schlomm Department of Urology, Charité, Universitätsmedizin Berlin, Berlin, Germany
  • Franziska Büscheck Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany

DOI:

https://doi.org/10.1080/0284186X.2019.1686537

Abstract

Background: Remodelling and spacing factor 1 (RSF1) is involved in the regulation of chromatin remodelling and represents a potential therapeutic target. High RSF1 expression has been linked to adverse tumour features in many cancer types, but its role in prostate cancer is uncertain.

Methods: In this study, RSF1 expression was analysed by immunohistochemistry on a tissue microarray with 17,747 prostate cancers.

Results: Nuclear RSF1 staining of 16,456 interpetable cancers was considered strong, moderate, weak and negative in 25.2%, 48.7%, 5.3% and 20.8% of cancers respectively. Positive RSF1 expression was associated with advanced tumour stage, high Gleason grade, lymph node metastasis (p < .0001 each), early biochemical recurrence (p < .0003) and more frequent in the ERG positive than in the ERG negative subset (88% versus 71%; p < .0001). Subset analysis revealed, that associations between RSF1 expression and unfavourable tumour phenotype and PSA recurrence were present in both subgroups but stronger in the ERG negative than in the ERG positive subset. The univariate Cox proportional hazard ratio for PSA recurrence-free survival for strong versus negative RSF1 expression was a weak 1.60 compared with 5.91 for the biopsy Gleason grade ≥4 + 4 versus ≤3 + 3. The positive association of RSF1 protein detection with deletion of 3p13, 10q23 (PTEN), 12p13, 16q23, and 17p13 (p < .0001 each) suggest a role of high RSF1 expression in the development of genomic instability.

Conclusion: In summary, the results of our study identify RSF1 as an independent prognostic marker in prostate cancer with a particularly strong role in ERG negative cases.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2020-03-03

How to Cite

Höflmayer, D., Hamuda, M., Schroeder, C., Hube-Magg, C., Simon, R., Göbel, C., … Büscheck, F. (2020). High RSF1 protein expression is an independent prognostic feature in prostate cancer. Acta Oncologica, 59(3), 268–273. https://doi.org/10.1080/0284186X.2019.1686537

Issue

Vol. 59 No. 3 (2020): Acta Oncologica

Section

Articles